Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
Serena Jingchuan GuoHuilin TangStephen R BenoitYing LuLizheng ShiVivian A FonsecaHwayoung ChoYi GuoJiang BianPublished in: Diabetes, obesity & metabolism (2024)
Compared to DPP4 inhibitors, SGLT2 inhibitors were associated with a significantly lower risk of incident PD in older populations with T2D.